Sir,

I read with interest the original article "Dyslipidemic drugs in metabolic syndrome" published by Siddiqui *et al*.\[[@ref1]\]

At the outset, I wish to compliment the authors for conducting first study which evaluated the lipid-lowering effect of rosuvastatin versus a combination of atorvastatin and ezetimibe in metabolic syndrome in the Indian patients. Their study result showed the combination of atorvastatin plus ezetimibe to be more efficacious than rosuvastatin. In terms of safety profile, combination of atorvastatin plus ezetimibe was found to be comparable to rosuvastatin. The results of this study will surely help clinicians to use combination of ezetimibe plus atorvastatin to achieve low-density lipoproteincholesterol (LDL-C) goal and avoid the risk of high-dose statin monotherapy in deserving patients.

I think inadvertently the title of original article has been given as "Dyslipidemic drugs in metabolic syndrome" instead of "Antidyslipidemic drugs in metabolic syndrome."

I feel, changing the title of the original article as "Antidyslipidemic drugs in metabolic syndrome" will help to attract more readers to study results and in turn more physicians will extend the benefit of combination to the patients who deserve this treatment.
